ADTX - Aditxt Inc.  logo

Aditxt Inc.

ADTX

Aditxt Inc. develops immune health products, including AditxtScore for personalized immune profiling and Apoptotic DNA Immunotherapy to retrain the immune system. The company focuses on addressing autoimmune diseases, organ rejection, and therapeutic innovations.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$0today

Score Overview

1 Year
Score—
Net Growth-24.54%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev Trend—
Revenue Consistency—
5 Years
Score2.6
Net Growth-12.03%
Net Trend20%
Net Income Consistency—
Rev Growth-86.35%
Rev Trend33%
Revenue Consistency—
All Time
Score—
Net Growth-467.83%
Net Trend17%
Net Income Consistency
Rev Growth—
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Aditxt Inc. has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ADTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 0.00—
1 Year2025-10-23
$ 7.3K-100.00%
5 Years2021-10-22
$ 1000K-100.00%
All Time2020-06-30
$ 1000K-100.00%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 14.34K-$ 51M$ 268.85K
2025-$ 41M$ 3M
2024$ 133.99K-$ 34M$ 833M
2023$ 645.18K-$ 32M$ 97.1K
2022$ 933.72K-$ 27M$ 2M
2021$ 105.03K-$ 46M$ 7M
IPO2020$ 0.00-$ 9M$ 10M
ADTX - Aditxt Inc.  logo

Aditxt Inc. fundamental performance

Between 2020 and 2025, net income went from -$ 9M to -$ 41M. Revenue increased in 2 of those 5 years; net income in 1.

Aditxt Inc. currently holds a 5-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.

Membership

Explore ADTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies